Trevi Therapeutics, Inc. (TRVI)
$12.06-1.87%Close
SELLCRISIS · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.7B
- Beta
- 0.98
- P/E (TTM)
- -35.70
- Short % float
- 12.33%
- Days to cover
- 8.3
- SI change
- +21.3%
- 1W
- -8.22%
- 1M
- -19.81%
- vs SPY 1W
- -7.24%
- vs SPY 1M
- -21.68%
Industry peers
FMP comparable companies · ranked by market cap
- ACADSELLAcadia Pharmaceuticals Inc.$3.2BCRISISQ 18$18.62+3.38%
- VCRESELLVicore Pharma Holding AB$2.5BQ -62$8.95+1.45%
- LQDASELLLiquidia Corporation$2.4BCRISISQ 14$26.81+26.59%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.4BCRISISQ 23$28.99-2.28%
- TBPHBUYTheravance Biopharma Inc$884MBULLQ -1$17.03+0.00%
- LXRXSELLLexicon Pharmaceuticals, Inc.$715MCRISISQ 5$1.61-0.62%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 20
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-14.2%
REV YoY-
ROE-23.6%
EPS YoY-
ROA-15.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-35.70
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B5.87
P/FCF-
EV/EBITDA-32.50
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.19
ALTMAN Z-
CURR RATIO37.28
ND/EBITDA-
BETA0.98
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
SELL
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
PROFIT FACTOR2.4
TRADES32
[REGIME]FULL HISTORY
CRISIS
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on TRVI?
- LOPJLB’s latest quantitative signal on Trevi Therapeutics, Inc. (TRVI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TRVI in?
- Trevi Therapeutics, Inc. (TRVI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Trevi Therapeutics, Inc. (TRVI) do?
- Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experien…